8-K 1 c79170ae8vk.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ---------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2003 MANHATTAN PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-27282 36-3898269 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 787 Seventh Avenue, 48th Floor New York, New York 10019 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (212) 554-4525 (Former Name or Former Address, if Changed Since Last Report) ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE. In accordance with the provisions of paragraph (d) of Rule 135c promulgated under the Securities Act of 1933, as amended, the Registrant has attached hereto as Exhibit 99.1 is its Preliminary Notice of Action to Be Taken by Written Consent of Stockholders in Lieu of a Special Meeting and Information Statement on Schedule 14C, which was filed with the Commission on August 15, 2003. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (c) Exhibits 99.1 Registrant's Preliminary Notice of Action to Be Taken by Written Consent of Stockholders in Lieu of a Special Meeting and Information Statement on Schedule 14C. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANHATTAN PHARMACEUTICALS, INC. Date: August 15, 2003 By: /s/ Nicholas J. Rossettos ----------------------------- Chief Operating Officer and Chief Financial Officer 2 EXHIBIT INDEX 99.1 Registrant's Preliminary Notice of Action to Be Taken by Written Consent of Stockholders in Lieu of a Special Meeting and Information Statement on Schedule 14C.